The Gilead laboratory in Foster City, California. The star performer for the company was its hepatitis C drug, Sovaldi, which generated US$3.5 billion in sales. Photo: Bloomberg The Gilead laboratory in Foster City, California. The star performer for the company was its hepatitis C drug, Sovaldi, which generated US$3.5 billion in sales. Photo: Bloomberg
The Gilead laboratory in Foster City, California. The star performer for the company was its hepatitis C drug, Sovaldi, which generated US$3.5 billion in sales. Photo: Bloomberg
Hari Kumar
Opinion

Opinion

My Take by Hari Kumar

Despite huge profits, Gilead Sciences defends price of its hepatitis drug

The Gilead laboratory in Foster City, California. The star performer for the company was its hepatitis C drug, Sovaldi, which generated US$3.5 billion in sales. Photo: Bloomberg The Gilead laboratory in Foster City, California. The star performer for the company was its hepatitis C drug, Sovaldi, which generated US$3.5 billion in sales. Photo: Bloomberg
The Gilead laboratory in Foster City, California. The star performer for the company was its hepatitis C drug, Sovaldi, which generated US$3.5 billion in sales. Photo: Bloomberg
READ FULL ARTICLE
Hari Kumar

Hari Kumar

Hari Kumar is a journalist based in Hong Kong since 2003.